Kelyniam Global, Inc.
Kelyniam Global manufactures medical devices, including custom prosthetic implants for cranial and facial reconstruction. It uses computer aided design and manufacturing to produce implants from medical grade polymers. The company develops and distributes its products to surgeons, payors, and health systems. Kelyniam Global is based in Canton, Connecticut.
No SEC Form 4 filings for $KLYG in the last 30 days.
See all $KLYG insider activity →Kelyniam Global reported 35% revenue growth and a return to profitability for the nine months ended September 30, 2026, compared to the same period in 2025. The company attributed the growth to the launch of Fusion and higher sales of CustomizedBone. Investors await detailed financial statements for further assessment.
CANTON, Conn., May 12, 2025 /PRNewswire/ -- Kelyniam Global, Inc. KLYG, a leading manufacturer of custom cranial and craniofacial implants, today announced its financial results for the first quarter ended March 31, 2025, and highlighted a new partnership to drive future growth.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning KLYG (Kelyniam Global, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KLYG coverage spans earnings and financial news.
Positive earnings update likely supports the stock.
Kelyniam Global announced strong Q1 2025 financial results alongside a strategic partnership, indicating potential growth and positive market sentiment.
AlphAI scores every news story that mentions KLYG with an AI model for sentiment and relevance, and aggregates insider trades from Kelyniam Global, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kelyniam Global reported 35% revenue growth and a return to profitability for the nine months ended September 30, 2026, compared to the same period in 2025. The company attributed the growth to the launch of Fusion and higher sales of CustomizedBone. Investors await detailed financial statements for further assessment.
CANTON, Conn., May 12, 2025 /PRNewswire/ -- Kelyniam Global, Inc. KLYG, a leading manufacturer of custom cranial and craniofacial implants, today announced its financial results for the first quarter ended March 31, 2025, and highlighted a new partnership to drive future growth.
